Impact of HLA class I alterations in cancer patients undergoing T cell specific immunotherapy

被引：0
|
作者：
Méndez, R [1 ]
Ruiz-Cabello, F [1 ]
Jiménez, P [1 ]
Cabrera, T [1 ]
López-Nevot, MA [1 ]
Knuth, A [1 ]
Jager, E [1 ]
Traversari, C [1 ]
Schadendorff, D [1 ]
Boon, T [1 ]
Garrido, F [1 ]
机构：
[1] Hosp Univ, Serv Anal Clin, Granada, Spain
来源：
TISSUE ANTIGENS | 2002年 / 59卷
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [41] HLA expression in cancer: implications for T cell-based immunotherapy
    Alessandro Sette
    Robert Chesnut
    John Fikes
    Immunogenetics, 2001, 53 : 255 - 263
  • [42] Synthetic HLA-independent T cell receptors for cancer immunotherapy
    Simon, Sylvain
    Bugos, Grace
    Riddell, Stanley R.
    CANCER CELL, 2022, 40 (04) : 359 - 361
  • [43] HLA expression in cancer: implications for T cell-based immunotherapy
    Sette, A
    Chesnut, R
    Fikes, J
    IMMUNOGENETICS, 2001, 53 (04) : 255 - 263
  • [44] Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
    Chowell, Diego
    Morris, Luc G. T.
    Grigg, Claud M.
    Weber, Jeffrey K.
    Samstein, Robert M.
    Makarov, Vladimir
    Kuo, Fengshen
    Kendall, Sviatoslav M.
    Requena, David
    Riaz, Nadeem
    Greenbaum, Benjamin
    Carroll, James
    Garon, Edward
    Hyman, David M.
    Zehir, Ahmet
    Solit, David
    Berger, Michael
    Zhou, Ruhong
    Rizvi, Naiyer A.
    Chan, Timothy A.
    SCIENCE, 2018, 359 (6375) : 582 - +
  • [45] Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
    Paulson, K. G.
    Voillet, V.
    McAfee, M. S.
    Hunter, D. S.
    Wagener, F. D.
    Perdicchio, M.
    Valente, W. J.
    Koelle, S. J.
    Church, C. D.
    Vandeven, N.
    Thomas, H.
    Colunga, A. G.
    Iyer, J. G.
    Yee, C.
    Kulikauskas, R.
    Koelle, D. M.
    Pierce, R. H.
    Bielas, J. H.
    Greenberg, P. D.
    Bhatia, S.
    Gottardo, R.
    Nghiem, P.
    Chapuis, A. G.
    NATURE COMMUNICATIONS, 2018, 9
  • [46] Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
    K. G. Paulson
    V. Voillet
    M. S. McAfee
    D. S. Hunter
    F. D. Wagener
    M. Perdicchio
    W. J. Valente
    S. J. Koelle
    C. D. Church
    N. Vandeven
    H. Thomas
    A. G. Colunga
    J. G. Iyer
    C. Yee
    R. Kulikauskas
    D. M. Koelle
    R. H. Pierce
    J. H. Bielas
    P. D. Greenberg
    S. Bhatia
    R. Gottardo
    P. Nghiem
    A. G. Chapuis
    Nature Communications, 9
  • [47] LOSS OF HLA CLASS-I EXPRESSION IN PROSTATE-CANCER - IMPLICATIONS FOR IMMUNOTHERAPY
    BLADES, RA
    KEATING, PJ
    MCWILLIAM, LJ
    GEORGE, NJR
    STERN, PL
    UROLOGY, 1995, 46 (05) : 681 - 686
  • [48] Analysis of HLA class I specific antibodies in patients with failed allografts
    Mao, Quanzong
    Terasaki, Paul I.
    Cai, Junchao
    El-Awar, Nadim
    Rebellato, Lorita
    TRANSPLANTATION, 2007, 83 (01) : 54 - 61
  • [49] Cancer-specific T cell receptor isolation for cancer immunotherapy
    Weigand, Luise U.
    Paston, Samantha
    Hibbert, Linda
    Ryan, Ruth K.
    Baker, Debbie E.
    Simmons, Ruth A.
    Harper, Jane V.
    Dukes, Joseph D.
    Bossi, Giovanna
    Grand, Francis
    Hickman, Emma
    Powlesland, Alex
    Vuidepot, Annelise
    Hassan, Namir J.
    Jakobsen, Bent K.
    CANCER RESEARCH, 2014, 74 (19)
  • [50] Cancer-specific T cell receptor isolation for cancer immunotherapy
    Ryan, Ruth
    Hibbert, Linda
    Weigand, Luise
    Paston, Samantha
    Baker, Debbie
    Donnellan, Zoe
    Clark, Vanessa
    Hale, Kathy
    Conlon, Louise
    Dukes, Joseph
    Boudousquie, Caroline
    Bossi, Giovanna
    Hickman, Emma
    Powlesland, Alex
    Vuidepot, Annelise
    Hassan, Namir
    Jakobsen, Bent
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
12345